18F-GP1 (GPIIb/IIIa Tracer)

May 21, 2026 — Lantheus Holdings, Inc. (NASDAQ: LNTH) announced new radiodiagnostic data it will present at the 2026 Society of Nuclear Medicine and Medical Imaging (SNMMI) Annual Meeting (May 30–June 2, 2026; Los Angeles).

The company highlighted two scheduled presentations: (1) a poster titled “Impact of PSMA-PET with Piflufolastat F18 on Prostate Cancer Management for Patients with Low or Ultra-low Prostate-Specific Antigen Levels after Definitive Treatment,” presented June 1, 2026 (poster #262453; presenter Neal Shore); and (2) an oral presentation on June 2, 2026 reporting “Diagnostic performance of 18F-GP1 PET/CT for acute deep vein thrombosis of the lower extremities in symptomatic patients,” described as a phase 2, open-label, non-randomized study (presenter Sangwon Han).

Business/clinical significance: the announcement signals continued clinical development and dissemination of evidence for Lantheus PET radiotracers in prostate cancer management and thrombus imaging, supporting adoption and potential future regulatory/market positioning, though no quantitative results are provided in the release.